Analysis of somatic mutations in BRAF, CDKN2A/p16 and PI3KCA in patients with medullary thyroid carcinoma

• Autor(a) principal: Nascimento, Fabricio P. [UNIFESP]
• Data de Publicação: 2016
• Outros Autores: Cardoso, Mirian G. [UNIFESP], Lindsey, Susan C. [UNIFESP], Kunii, Ilda S. [UNIFESP], Valente, Flavia O. F. [UNIFESP], Kizys, Marina M. L. [UNIFESP], Delcelo, Rosana [UNIFESP], Camacho, Cleber P. [UNIFESP], Maciel, Rui M. B. [UNIFESP], Dias-da-Silva, Magnus R. [UNIFESP]
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNIFESP
• Texto Completo: https://doi.org/10.3892/mmr.2015.4731; https://repositorio.unifesp.br/handle/11600/58475
• topic: medullary thyroid cancer; somatic mutation; RET; BRAF; RAS; CDKN2A; PI3KCA

Medullary thyroid carcinoma (MTC), a neuroendocrine tumor originating from thyroid parafollicular cells, has been demonstrated to be associated with mutations in RET, HRAS, KRAS and NRAS. However, the role of other genes involved in the oncogenesis of neural crest tumors remains to be fully investigated in MTC. The current study aimed to investigate the presence of somatic mutations in BRAF, CDKN2A and PI3KCA in MTC, and to investigate the correlation with disease progression. DNA was isolated from paraffin-embedded tumors and blood samples from patients with MTC, and the hotspot somatic mutations were sequenced. A total of 2 novel HRAS mutations, p.Asp33Asn and p.His94Tyr, and polymorphisms within the 3' untranslated region (UTR) of CDKN2A (rs11515 and rs3088440) were identified, however, no mutations were observed in other genes. It was suggested that somatic point mutations in BRAF, CDKN2A and PI3KCA do not participate in the oncogenesis of MTC. Further studies are required in order to clarify the contribution of the polymorphisms identified in the 3' UTR of CDKN2A in MTC.